Axin-2/BCL2 axis regulates apoptosis upon targeting TAM kinase

The Cellular Battlefield: When Good Guys Turn Bad

Imagine your body is a bustling, high-tech city. Inside this city, there are millions of tiny workers called cells, each with a specific job. Some build roads, others deliver mail, and some act as the immune system's security guards, hunting down invaders. But sometimes, a glitch happens in the city's blueprint. A cell gets a bad instruction, starts copying itself too fast, and ignores the "stop" signs. In the world of blood cells, this glitch leads to leukemia, a type of cancer where abnormal white blood cells multiply wildly, crowding out the healthy ones and causing the body to run out of oxygen and clotting power.

To fight this, scientists look at the "on switches" on the surface of these rogue cells. One famous group of switches is called TAM receptors (named after three friends: Tyro3, Axl, and MerTk). Think of TAM receptors as the cell's personal doorbells. In a healthy city, these doorbells ring only when necessary. But in leukemia, the doorbells are stuck in the "ringing" position, constantly shouting, "Keep growing! Don't die!" This keeps the cancer cells alive and resistant to treatment. Scientists have developed special "jamming devices" (inhibitors) to block these doorbells, hoping to force the cancer cells to finally listen to their internal "self-destruct" button, known as apoptosis. However, not all cancer cells react the same way; some jam the signal, while others just ignore it. The big question is: why do some cells surrender while others fight back?

The Paper's Discovery: The Axin-2 vs. BCL2 Tug-of-War

In this study, the researchers decided to play detective with four different types of leukemia cell lines: two from Acute Myeloid Leukemia (AML), one from Chronic Myeloid Leukemia (CML), and one from Acute Lymphocytic Leukemia (ALL). They treated these cells with their TAM receptor jamming devices at various strengths, ranging from 0.3 to 1.5 micromolars (µM).

The first clue they found was a clear split in the battlefield. The AML cells (specifically the Kasumi-1 and Molm-13 lines) were very sensitive to the jamming devices. When the researchers used concentrations around 500 nanomolars (nM), these cells stopped growing and started dying. In contrast, the CML (K562) and ALL (Jurkat) cells were tough cookies. Even when hit with a stronger dose of 1.5 µM, they barely flinched, continuing to multiply. This suggested that simply blocking the TAM doorbells wasn't enough to kill every type of leukemia; something else inside the cells was deciding the outcome.

Digging deeper, the team looked at the internal wiring of these cells, specifically focusing on a famous signaling pathway called "Canonical WNT." Inside this pathway, there is a protein called Axin-2, which acts like a brake pedal for cell growth and a trigger for self-destruction. There is also a protein called BCL2, which acts like a shield, protecting the cell from dying. The researchers discovered a fascinating seesaw relationship between these two proteins.

In the sensitive AML cells (Kasumi-1), blocking the TAM receptors caused the Axin-2 brake to slam down hard while the BCL2 shield disappeared. This combination forced the cells to self-destruct. However, in the resistant cells (K562 and Jurkat), the opposite happened: the Axin-2 brake stayed weak, and the BCL2 shield remained thick, effectively blocking the self-destruct signal. The paper suggests that this "Axin-2/BCL2 axis" is the real boss deciding whether the cell dies or survives.

There was a twist in the Molm-13 AML cells. Even though they had high levels of Axin-2 (the good guy) and high levels of BCL2 (the bad guy), they still stopped growing. The researchers found that these cells also had high levels of a protein called c-Myc. They propose that in this specific case, the high BCL2 shield was strong enough to stop the c-Myc protein from killing the cell, but the jamming device still managed to put the cell on "pause" (cell cycle arrest) rather than killing it outright.

The study also checked other signaling pathways, like RAS/MAPK and PI3K/AKT, which are often involved in cancer growth. Surprisingly, in the sensitive Kasumi-1 cells, these pathways actually went up after treatment, yet the cells still died. This proved that the Axin-2/BCL2 relationship was the dominant factor, overriding the other signals.

What This Means for the Future

The researchers conclude that the success of blocking TAM receptors depends entirely on the balance between Axin-2 and BCL2. If a leukemia cell has high Axin-2 and low BCL2, the treatment works like a charm. If it has low Axin-2 and high BCL2, the cell resists the treatment. The paper suggests that for the resistant types of leukemia (like CML and ALL), simply blocking the TAM receptors isn't enough. Instead, doctors might need to find a way to break the "Axin-2/BCL2 axis"—perhaps by forcing the Axin-2 up or knocking the BCL2 shield down—to make these stubborn cells finally surrender. While this is a significant step in understanding the mechanics of resistance, the authors present these findings as a proposed mechanism based on their lab experiments, highlighting a new target for future therapies rather than a cure that is ready for patients today.